index,nct_id,display_order,candidate_criteria_text,score,hedging
389,NCT04742634,4,"Must have undergone gene panel testing prior to the start of transplant conditioning and must have at least one somatically acquired mutation that is interrogated by the MyeloSeq-HD panel. If the patient has a variant that is known to be a germline/inherited myeloid predisposition gene in that patient, this variant cannot and will not be used as evidence of MRD positivity. If the pre-transplant gene panel testing is a next-generation sequencing panel other than the MyeloSeq platform, the outside report will be reviewed by the principal investigator (PI) and the molecular pathologists at the McDonnell Genome Institute to ensure eligibility.",0.9743830561637878,true
65,NCT03602157,14,PRIOR TO CELL PROCUREMENT: Subjects must not have a history of intolerance to fludarabine. Subjects with an intolerance to bendamustine may be allowed to enroll at the discretion of the clinical investigator if he/she thinks that the subject is a candidate for lymphodepletion with cyclophosphamide and fludarabine.,0.9743155837059021,true
238,NCT04423211,5,"Patients must have no definite evidence for extrapelvic metastatic disease. This may be determined by CIM (CT abdomen/pelvis or MRI abdomen/pelvis AND bone scintigraphy or equivalent) within 26 weeks prior to step 0 registration. If patient does not have prior CIM, an existing study-eligible = PET using FDA-approved radiotracer may be used to determine whether patient requires CIM.
For patients who have study-eligible PET done without prior CIM:
* Baseline CIM is required if the study-eligible PET is positive for extrapelvic lesions. Patient should have a baseline CT/MRI (e.g. for soft tissue lesions) and performed within 16 weeks prior to study registration./or a bone scan (e.g. for osseous lesions), for further evaluation of the PET-detected extrapelvic lesion(s).
* Baseline CIM is not required if the study-eligible PET is negative for extrapelvic lesions.
NOTE: Extra-pelvic metastases are defined as extrapelvic soft tissue, lymph node and organ metastases, and/or any osseous metastases; extra-pelvic is defined as superior to common iliac bifurcation, and/or outside of standard fields for prostate bed + whole pelvis nodal RT fields",0.9740725755691528,true
306,NCT04579224,20,"Participants must not be pregnant or nursing due to the risk of harm to a fetus or nursing infant. Women and men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study and 6 months (females) or 3.5 months (males) after the last dose. A woman is considered to be of ""reproductive potential"" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, ""effective contraception"" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures",0.9733515977859497,true
322,NCT04585958,24,"Patients who are human immunodeficiency virus (HIV) positive may participate IF they meet the following eligibility requirements:
* They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective 
* They must have an undetectable viral load and a CD4 count >= 250 cells/uL within 7 days of enrollment
* They must not be currently receiving prophylactic therapy for an opportunistic infection and must not have had an opportunistic infection within the past 6 months
* HIV-infected patients should be monitored every 12 weeks for viral load and CD4 counts",0.9733006954193115,true
253,NCT04484012,2,"Participants must agree to allow the use of archival tissue from diagnostic tumor biopsies
* If unavailable, exceptions may be granted with study principal investigator (PI) approval
Note: For research participants who do not speak English, a short form consent may be used with a City of Hope (COH) certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated full consent is processed",0.9731103181838989,true
63,NCT03602157,4,"PRIOR TO CELL PROCUREMENT: Diagnosis of recurrent lymphoma in subjects who have failed >= 2 prior treatment regimens.
* These prior treatment regimens must include brentuximab vedotin.
* If the subject has Hodgkin lymphoma, the subject must have either failed autologous transplant or must not be eligible for autologous transplant.
* If the subject has grey zone lymphoma, the subject must have failed an anthracycline containing regimen unless the subject was not previously a candidate for anthracycline.
* Subjects relapsed after autologous or allogeneic stem cell transplant are eligible for this study.",0.9730885624885559,true
32,NCT03180268,13,"If the patient is a woman is of childbearing potential, a serum pregnancy test, obtained within 14 days prior to step 2 registration, must be negative, and, if randomized to receive radiation therapy, the woman must agree to use contraception",0.9730424880981445,true
293,NCT04548752,31,"Participants must not be pregnant or nursing due to the possibility of harm to the fetus or nursing infant from this treatment regimen. Women of childbearing potential must have a negative urine or serum pregnancy test within 28 days prior to registration. Women/men of reproductive potential must have agreed to use an effective contraceptive method for the course of the study through 6 months after the last dose of study medication. A woman is considered to be of ""reproductive potential"" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, ""effective contraception"" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures, he/she is responsible for beginning contraceptive measures. Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately",0.97299724817276,true
112,NCT03710421,2,"Agreement to allow the use of archival tissue from diagnostic tumor biopsies 
* If unavailable, exceptions may be granted with study primary investigator approval
Note: For research participants who do not speak English, a short form consent may be used with a COH certified interpreter/translator to proceed with screening and leukapheresis, while the request for a translated full consent is processed.",0.9728404879570007,true
418,NCT04852887,5,"The patient must have undergone a lumpectomy and the margins of the resected specimen or re-excision must be histologically free of invasive tumor and breast ductal carcinoma in situ (DCIS) with no ink on tumor as determined by the local pathologist. If pathologic examination demonstrates tumor at the line of resection, additional excisions may be performed to obtain clear margins. (Patients with margins positive for breast lobular carcinoma in situ [LCIS] are eligible without additional resection)",0.9727608561515808,true
302,NCT04579224,5,"Participant must have had prior systemic therapy in metastatic setting that:   
* Included enfortumab vedotin 
* Included a PD1/PDL1 antibody
** NOTE: Under the discretion of the treating physician, participants who are not candidates for PD1/PDL1 antibody systemic therapy are allowed
* Any systemic therapy provided in adjuvant, neoadjuvant, or chemoradiation settings for urothelial carcinoma can be considered to be in metastatic setting, if the last day of treatment was within 12 months prior to the diagnosis of metastatic disease",0.9727421402931213,true
349,NCT04671667,9,"Patient must not have received anti-PD-1/PD-L1 therapy for recurrent disease. If the patient received anti-PD-1/PD-L1 therapy as part of initial upfront curative intent treatment (either as part of definitive non-surgical therapy or in the adjuvant setting) in the past, the last dosage of anti-PD-1/PD-L1 therapy must have been given greater than one year prior to randomization",0.9727118015289307,true
132,NCT03761108,9,"Refractory disease is defined as progression during treatment or within 60 days after completion of therapy, or <25% response to therapy. AND, for ALL patients, if they have relapsed after a BCMA-directed CAR-T cellular therapy then: • Treatment with a CAR-T must have been associated with a response of PR or better, and • If CAR-T cellular therapy was the most recent prior therapy, excluding corticosteroids, then treatment must have been a minimum of 60 days prior to treatment with REGN5458. Key",0.9726412892341614,true
58,NCT03488693,15,"RT must commence within 16 weeks of definitive surgery if the patient is not treated with chemotherapy; if adjuvant chemotherapy is given, RT must begin within 12 weeks after the last dose; (Note: adjuvant chemotherapy may be ongoing at the time of randomization)
* Note: Definitive surgery is defined as the last breast cancer-related surgery",0.9725870490074158,true
363,NCT04691817,6,"Prior exposure and disease progression during at least 1 line of therapy including a checkpoint inhibitor. This may include a single checkpoint inhibitor, therapy with two checkpoint inhibitors simultaneously, or chemotherapy and immunotherapy combined or in sequence and must be the line immediately prior to enrollment on the trial. Prior PD-L1 inhibitors are permitted, since the goal of the study is to see if interleukin (IL) 6 inhibition can relieve resistance to immune checkpoint inhibitors",0.9725604057312012,true
48,NCT03465592,7,"Subjects must consent to allow for a baseline tumor biopsy. If a biopsy is not feasible, then archival tumor material must be made available. Tumor biopsies to be taken (if a subject’s tumor is thought to be reasonably safe and easy to biopsy) at baseline (any time prior to the first dose after eligibility is met) and at cycle 2 (4-6 cores per time point) or when lesions are visualized on physical examination or imaging studies in the case of no identifiable masses at cycle 2. Additional optional biopsies may be obtained later in the course of study treatment. Detailed instructions for tissue collection, processing and shipment are provided. The proposed investigation is considered a non-significant risk (NSR). A significant risk procedure is generally considered to be one for which the procedure-associated absolute risk of mortality or major morbidity, in the patient’s clinical setting and at the institution completing the procedure, is 2% or higher. Diagnostic Tissue Samples Tissue, fluid, or blood may be collected from standard of care procedures used to treat or diagnose immune related toxicities/graft versus host disease (GVHD).",0.9724776744842529,true
83,NCT03602157,59,PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: ANC > 1000 cells/mm^3. Subjects cannot have received platelet transfusion within 7 days of lymphodepletion. Note: Subjects may receive a second infusion without prior lymphodepletion or with a 25-50% dose reduction in bendamustine if they meet all other eligibility criteria at the time of infusion.,0.9722647666931152,true
84,NCT03602157,60,"PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: Platelets > 50,000/mm^3. Subjects cannot have received platelet transfusion within 7 days of lymphodepletion. Note: Subjects may receive a second infusion without prior lymphodepletion or with a 25-50% dose reduction in bendamustine if they meet all other eligibility criteria at the time of infusion.",0.9722527265548706,true
379,NCT04691817,48,"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, as defined below: Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the final dose of atezolizumab. A woman is considered to be of childbearing potential if she is post-menarche, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus) or another cause as determined by the investigator (e.g., Müllerian agenesis). Per this definition, a woman with a tubal ligation is considered to be of childbearing potential. The definition of childbearing potential may be adapted for alignment with local guidelines or requirements. Examples of contraceptive methods with a failure rate of < 1% per year include bilateral tubal ligation, male sterilization, hormonal contraceptives that inhibit ovulation, hormone-releasing intrauterine devices, and copper intrauterine devices. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or post-ovulation methods) and withdrawal are not acceptable methods of contraception. If required per local guidelines or regulations, locally recognized adequate methods of contraception and information about the reliability of abstinence will be described in the local informed consent form
For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use a condom, and agreement to refrain from donating sperm, as defined below: With a female partner of childbearing potential or pregnant female partner, men must remain abstinent or use a condom during the treatment period and for 5 months after the final dose of atezolizumab to avoid exposing the embryo. Men must refrain from donating sperm during this same period. The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of preventing drug exposure. If required per local guidelines or regulations, information about the reliability of abstinence will be described in the local informed consent form",0.972018837928772,true
59,NCT03488693,22,"Women of childbearing potential must have agreed to use an effective contraceptive method; a woman is considered to be of ""childbearing potential"" if she has had menses at any time in the preceding 12 consecutive months; in addition to routine contraceptive methods, ""effective contraception"" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation, or vasectomy/vasectomized partner; however, if at any point a previously celibate patient chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, she is responsible for beginning contraceptive measures
* Women of childbearing potential will have a pregnancy test to determine eligibility as part of the Pre-Study Evaluation; this may include an ultrasound to rule-out pregnancy if a false-positive is suspected; for example, when beta-human chorionic gonadotropin is high and partner is vasectomized, it may be associated with tumor production of human chorionic gonadotropin (hCG), as seen with some cancers; patient will be considered eligible if an ultrasound is negative for pregnancy",0.9719836711883545,true
221,NCT04340882,16,"Clinically significant toxic effect(s) of the most recent prior anti-cancer therapy must be grade 1 or resolved (except alopecia and sensory neuropathy); patients with grade 2 adrenal insufficiency related to prior anti-cancer therapy (defined as requiring medical intervention, such as concomitant steroids) or grade 2 hypothyroidism (defined as requiring hormone replacement therapy) may be enrolled provided that clinical symptoms are adequately controlled and the daily dose is 10 mg or less of prednisone or equivalent. If the patient received major surgery or radiation therapy of > 30 Gy, they must have recovered from the toxicity and/or complications from the intervention",0.9719669222831726,true
72,NCT03602157,29,PRIOR TO LYMPHODEPLETION: Bilirubin =< 1.5 times the upper limit of normal (ULN). Subjects with Gilbert's syndrome may be treated despite a total bilirubin level > 1.5 mg/dL if their conjugated bilirubin is < 1.5 x ULN).,0.9717884063720703,true
66,NCT03602157,17,PRIOR TO PROCUREMENT: Bilirubin =< 1.5 times the upper limit of normal (ULN). Subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level > 1.5 mg/dL if their conjugated bilirubin is < 1.5 x ULN).,0.9717446565628052,true
85,NCT03602157,61,PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: Bilirubin =< 1.5 times the upper limit of normal (ULN). Subjects with Gilbert's syndrome may be enrolled despite a total bilirubin level > 1.5 mg/dL if their conjugated bilirubin is < 1.5 x ULN),0.9715377688407898,true
43,NCT03277638,24,Active tumor must be Unifocal & Unilateral. Two enhancing nodules within the same fluid attenuated inversion recovery (FLAIR) hyperintense region are still eligible; 1-2 secondary enhancing or non-enhancing lesions may be present as long as they have been radiologically stable for >= 3 mo),0.9714143872261047,true
57,NCT03488693,14,Patients may or may not have had adjuvant chemotherapy,0.971271276473999,true
78,NCT03602157,45,PRIOR TO LYMPHODEPLETION: Subjects must not be using systemic corticosteroids at doses >= 10mg prednisone daily or its equivalent; those receiving < 10mg daily may be treated at discretion of the investigator.,0.971189558506012,true
121,NCT03734692,3,Patients must have completed prior platinum-based therapy. Response can be complete or partial if it otherwise meets platinum sensitive criteria.,0.9710686802864075,true
82,NCT03602157,58,PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: Must not have current use of systemic corticosteroids at doses >= 10 mg prednisone daily or its equivalent; those receiving < 10 mg daily may be enrolled at discretion of the Investigator.,0.9708973169326782,true
278,NCT04548752,8,"Patients must have received at least 16 weeks of first line platinum-based chemotherapy for metastatic disease. Patients may have also received one cycle of treatment (no more than 4 weeks) with gemcitabine + nab-paclitaxel while waiting for germline test results, prior to platinum-based therapy",0.97087562084198,true
464,NCT04919369,20,"For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods, and agreement to refrain from donating eggs, as defined below:
* Women must remain abstinent or use contraceptive methods with a failure rate of < 1% per year during the treatment period and for 5 months after the final dose of atezolizumab or ATRA. Women must refrain from donating eggs during this same period. 
* A woman is considered to be of childbearing potential if she is postmenarchal, has not reached a postmenopausal state (>= 12 continuous months of amenorrhea with no identified cause other than menopause), and has not undergone surgical sterilization (removal of ovaries and/or uterus).  The definition of childbearing potential may be adapted for alignment with local guidelines or requirements.
* The reliability of sexual abstinence should be evaluated in relation to the duration of the clinical trial and the preferred and usual lifestyle of the patient.  Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not adequate methods of contraception.",0.970866858959198,true
64,NCT03602157,11,PRIOR TO CELL PROCUREMENT: Subjects must not be using systemic corticosteroids at doses >= 10mg prednisone daily or its equivalent; those receiving < 10mg daily may be enrolled at discretion of the investigator.,0.9707805514335632,true
60,NCT03556228,0,"Histologically or cytologically confirmed diagnosis of any type of solid tumor malignancy or lymphoma that is not responsive to standard therapies or had progressed following standard therapy and for which there is no approved or curative therapy. Additionally, patients must not be candidates for or have exhausted regimens known to provide clinical benefit, including hematopoietic stem cell transplantation in lymphoma patients if they are deemed transplant eligible.",0.970725417137146,true
263,NCT04493203,4,"Progressed on prior anti-PD1 therapy with or without anti-CTLA4 therapy. Patients may have progressed in the adjuvant setting if treated within the last 6 months. Prior treatment with BRAF/MEK inhibitors permitted, however, not required. Progression must be radiographic, and progression of disease will be confirmed by a radiologist. Patients must have progressed during anti-PD-1 therapy, defined as unequivocal progression on or within 3 months of the last dose of anti-PD-1 therapy if treated in the metastatic setting, or within 6 months if treated in the adjuvant setting",0.970680832862854,true
235,NCT04419519,10,"If receiving venetoclax in combination with anti-CD20 monoclonal antibody, patients must have completed or discontinued the anti-CD20 monoclonal antibody portion of the regimen prior to discontinuing therapy",0.9706672430038452,true
56,NCT03488693,13,"Patients must have had endocrine therapy initiated or planned for >= 5 years; premenopausal women will receive ovarian ablation plus aromatase inhibitor therapy or tamoxifen if adjuvant chemotherapy was not administered; for all patients, endocrine therapy can be given concurrently or following RT",0.9705881476402283,true
366,NCT04691817,10,"Availability of a representative paraffinized tumor specimen for exploratory biomarker research. A formalin-fixed paraffin-embedded (FFPE) tumor specimen in a paraffin block (preferred) or at least 10-15 slides containing unstained, freshly cut, serial sections should be submitted along with an associated pathology report prior to study enrollment. PDL1 status, which should be done as a standard of care for first line immunotherapy, will be recorded on a case report form. A biopsy may also be performed at screening if a patient's archival tissue test results do not meet eligibility criteria",0.9705392122268677,true
89,NCT03602157,67,"PRIOR TO LYMPHODEPLETION FOR OPTIONAL REINFUSION: Subjects cannot be on strong inhibitors of CYP1A2 (e.g., fluvoxamine, ciprofloxacin) as these may increase plasma concentrations of bendamustine, and decrease plasma concentrations of its metabolites.",0.9703441858291626,true
497,NCT04977024,11,Women of childbearing potential (WOCBP): negative urine or serum pregnancy test (to be performed within 30 days prior to day 0 of protocol therapy unless otherwise stated). If the urine pregnancy test is inconclusive a serum pregnancy test will be required,0.9702517986297607,true
490,NCT04971499,20,"Prior adverse events from anticancer therapy must be resolved to =< grade 1, with the exception of alopecia or endocrinopathies, which may be on replacement therapy. Prednisone equivalent of =< 10 mg is allowed.",0.9702328443527222,true
240,NCT04423211,9,"Patient must not have started short term ADT for biochemical recurrence prior to baseline PET (PET1), but may start short term ADT after PET and up to 7 days prior to study registration.
* NOTE:  A short course (e.g., ~ 4 weeks) of low-dose anti-androgen (e.g. bicalutamide), started given after PET1, either before or after study registration, is also permitted as a brief temporizing measure/bridge to protocol-approved SOC short term ADT",0.9701147079467773,true
100,NCT03618550,18,"Female subject of childbearing potential should have a negative urine or serum pregnancy within 2 weeks prior to receiving the first dose of study medication. On the day of planned treatment, if a blood pregnancy test has not been performed within the two week window, a stat pregnancy test (urine or blood) should be performed and the results reviewed before treatment is begun",0.9701029062271118,true
297,NCT04548752,35,"Patients must be offered the opportunity to participate in specimen banking of formalin-fixed paraffin-embedded (FFPE) tissue and whole blood. If a patient is unable to submit archival tissue, should the patient need to undergo a standard of care biopsy per National Comprehensive Cancer Network (NCCN) guidelines, patients must then be offered the opportunity to submit the fresh tumor tissue from that biopsy. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System",0.9700313210487366,true
428,NCT04858334,10,"Patient must have undergone at least 3 combined months (i.e., 12 weeks) of perioperative (neoadjuvant, adjuvant or a combination of both) systemic, multi-agent chemotherapy. Patients may have had up to 6 months of perioperative systemic therapy as deemed appropriate by their primary treating medical team (patients can have received radiation or chemoradiation in addition to this 6 months course)",0.9699516892433167,true
446,NCT04876456,7,Subjects with late relapse (> 2 years from previous chemotherapy) not amenable to resection are eligible if they have received first line platinum based chemotherapy and are deemed not amenable to surgical resection (no need for 1 salvage regimen in late relapse patients to be eligible),0.9696409106254578,true
55,NCT03488693,10,"Patients must have an Oncotype DX recurrence score =< 25 obtained from testing of breast tumor tissue from a core biopsy or from the surgical specimen
* If the patient does not already have Oncotype DX recurrence score, specimen (unstained blocks or slides) must be sent to the Exact Sciences centralized laboratory in Redwood City, California
* Oncotype DX testing must be performed on a core biopsy PRIOR to commencement of neoadjuvant endocrine therapy",0.9695544242858887,true
178,NCT04189757,12,"Platelet count > 75,000/mm^3
* Patients who have bone marrow infiltration by MCL are eligible if their ANC is >= 500/mm^3 (growth factor allowed) or their platelet level is equal to or > 20,000/mm^3. These patients should be discussed with either the PI or co-PI of the study for final approval",0.9695333242416382,true
362,NCT04691817,5,"No evidence of an EGFR, ALK, ROS1, BRAF or other driver mutation for which targeted therapy would be preferable or standard of care (consult principal investigator if there is a question of the nature of the mutation)",0.9695037603378296,true
388,NCT04742634,2,"Diagnosis of myelodysplastic syndromes (MDS) based on World Health Organization classification (2016 revision) who have received an allogeneic hematopoietic cell transplant. Any stem cell source, conditioning regimen, and immunosuppression regimen as determined by the treating physician, per institutional guidelines, is permitted. Patients may have received any therapy, or no therapy, prior to transplant.",0.9695011973381042,true
6,NCT02452008,17,"Men of reproductive potential and those who are surgically sterilized (i.e., postvasectomy) must agree to practice effective barrier contraception that has an expected failure rate of < 1% during and for 6 months after discontinuation of study treatment
* If condoms are used as a barrier contraceptive, a spermicidal agent should be added to ensure that pregnancy does not occur",0.9694104194641113,true
351,NCT04671667,12,"Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A urine or serum pregnancy test must be repeated within 72 hours prior to receiving the first dose of pembrolizumab or chemotherapy if the test done for eligibility/randomization is done outside of this 72 hour window. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. A patient of childbearing potential is someone, regardless of whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)",0.9693906903266907,true
309,NCT04585958,3,"Patients must have HER2-positive or HER2-expressing tumors determined by a Clinical Laboratory Improvement Act (CLIA)-certified laboratory. Specific requirement of HER2 status is outlined below:
* Dose Escalation Module 1 and Module 2:
** HER2 1-3+ expression by IHC OR
** HER2 amplification by next generation sequencing panel (NGS) or in situ hybridization (ISH) OR
** If local testing is not feasible, patients will submit archival tissue for central HER2 testing to determine eligibility. Patients with unknown or negative HER2 testing will not be eligible
* Dose Escalation Module 3:
** HER2 1-2+ expression by IHC OR
** HER2 amplification by next generation sequencing panel (NGS) or in situ hybridization (ISH) OR
** If local testing is not feasible, patients will submit archival tissue for central HER2 testing to determine eligibility. Patients with unknown or negative HER2 testing will not be eligible",0.9693374037742615,true
220,NCT04340882,15,Palliative radiotherapy (to bone or soft tissue lesions) must be completed > 1 week prior to start of study drug (exception: palliative radiotherapy for pain may be used any time prior to first dose),0.9690435528755188,true
305,NCT04579224,18,Participants must not be planning to take strong or moderate CYP3A or CYP2C8 inhibitors or inducers if randomized to Arm 1 and standard of care (SOC) regimen chosen is paclitaxel or docetaxel. Participants receiving strong or moderate CYP3A- or CYP2C8 inducers must discontinue use at least 2 weeks prior to randomization,0.9689526557922363,true
213,NCT04340882,6,Have measurable disease based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Lesions situated in a previously irradiated area are considered measurable if progression has been demonstrated in such lesions,0.9689483046531677,true
177,NCT04189757,11,"Absolute neutrophil count (ANC) > 1,000/mm^3
* Patients who have bone marrow infiltration by mantle cell lymphoma (MCL) are eligible if their ANC is >= 500/mm^3 (growth factor allowed) or their platelet level is equal to or > 20,000/mm^3. These patients should be discussed with either the principal investigator (PI) or co-PI of the study for final approval",0.9689446091651917,true
266,NCT04493203,19,"Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 7 months after the last dose of study therapy
* Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject",0.9688994288444519,true
396,NCT04742634,15,"Total bilirubin =< 1.5 x institutional upper limit of the normal (IULN).
* NOTE: If, in the opinion of the treating physician, bilirubin is elevated secondary to hemolysis or Gilbert’s disease, the patient may be eligible after discussion with the Washington University PI.",0.968864917755127,true
426,NCT04858334,5,"Patient must (1) be planning to receive, (2) be receiving or (3) have received at least three combined months (i.e., 12 weeks) of perioperative (neoadjuvant, adjuvant or a combination of both) systemic, multi-agent chemotherapy. Patients may have had up to 6 months of perioperative systemic therapy as deemed appropriate by their primary treating medical team (patients can have received radiation or chemoradiation in addition to this 6 month course)",0.9688445925712585,true
77,NCT03602157,39,"PRIOR TO LYMPHODEPLETION: Subjects cannot be on strong inhibitors of CYP1A2 (e.g., fluvoxamine, ciprofloxacin) as these may increase plasma concentrations of bendamustine, and decrease plasma concentrations of its metabolites. (This applies to subjects who receive bendamustine for lymphodepletion [required] up through 72 hours after the last dose of bendamustine).",0.9688229560852051,true
70,NCT03602157,27,PRIOR TO LYMPHODEPLETION: Presence of active disease by imaging and/or cutaneous involvement. Imaging must be performed within 7 days prior to lymphodepletion to confirm presence of active disease. Subjects who have received bridging chemotherapy must have imaging performed at least 3 weeks after most recent therapy (imaging does not need to be repeated if it is within 7 days prior to lymphodepletion).,0.9688020348548889,true
427,NCT04858334,6,"Patient must be no more than 12 weeks from their most recent treatment (this may be chemotherapy, radiotherapy or surgery)",0.9686107635498047,true
383,NCT04713046,7,PATIENT: Measurable disease using Response Evaluation Criteria In Solid Tumors (RECIST) 1.1. Tumor lesions situated in a previously irradiated area are considered measurable if progression has been documented in such lesions,0.9685253500938416,true
380,NCT04713046,3,"PATIENT: Have a human leukocyte antigen (HLA) partially mismatched (haploidentical) related donor. Acceptable donors include first degree relatives (parent, child, or haploidentical sibling), half-siblings, or second degree relatives (aunt, uncle, cousin, niece, nephew). A patient who has inherited a recombinant haplotype from the parents is eligible if the donor shares at least 1 HLA antigen at each of the HLA-A, -B, and DR loci",0.968496561050415,true
502,NCT05002816,14,"Male participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. Male participants are eligible to participate if they agree to the following during the intervention period and for 6 months after the last dose of study treatment to allow for clearance of any altered sperm:
* Refrain from donating sperm 
PLUS either:
* Be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis) and agree to remain abstinent.
OR
* Must agree to use contraception/barrier as detailed below:
** Agree to use a male condom, even if they have undergone a successful vasectomy, and female partner to use an additional highly effective contraceptive method with a failure rate of < 1% per year as when having sexual intercourse with a woman of childbearing potential (including pregnant females)",0.9683703780174255,true
2,NCT02452008,3,Patients may be receiving continuous hormonal ablation with surgical or medical castration with baseline testosterone < 50ng/dL,0.9680805802345276,true
120,NCT03734692,2,"Patients must have first or second peritoneal recurrence of epithelial adenocarcinoma or carcinosarcoma of ovarian, tubal or peritoneal origin:
* Histologic documentation of the original primary tumor is required via the pathology report.
* Original tumor blocks from the primary diagnosis will be requested by our study pathologist at Magee-Women’s Hospital of University of Pittsburgh Medical Center (UPMC) Cancer Centers. Original tumor blocks may be reviewed after registration (informed consent and enrollment).",0.9679551124572754,true
267,NCT04508790,7,"Relapsed or refractory to at least 1 prior line of therapy, including both a proteasome inhibitor and an immunomodulatory drug, and for whom transplant is not recommended. Participants may opt for a delayed transplant at a later time, if appropriate",0.9679408669471741,true
300,NCT04567771,9,"Computed tomography (CT), magnetic resonance imaging (MRI), positron emission tomography (PET)/CT, or PET/MRI for staging before registration; may be pre-operative (op) or post-op",0.9679190516471863,true
110,NCT03708224,18,"Male subjects must agree to use an adequate method of contraception and refrain from donating sperm, starting with the first dose of study therapy through 5 months after the last dose of study therapy.
* Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject",0.9678640961647034,true
501,NCT05002816,13,"Female participants: contraceptive use should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies. A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies:
* Is not a woman of childbearing potential (WOCBP) OR
* Is a WOCBP and using a contraceptive method that is highly effective (with a failure rate of < 1% per year), preferably with low user dependency, during the intervention period and for at least 4 months after the last dose of study intervention and agrees not to donate eggs (ova, oocytes) for the purpose of reproduction during this period. The investigator should evaluate the effectiveness of the contraceptive method in relationship to the first dose of study intervention.
A WOCBP must have a negative highly sensitive serum pregnancy test (as required by local regulations) within 72 hours before the first dose of study intervention.
The investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with a nearly undetected pregnancy.
Nonchildbearing potential is defined as follows (by other than medical reasons):
* >= 45 years of age and has not had menses for > 1 year
* Patients who have been amenorrhoeic for < 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation
* Post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure",0.9675955176353455,true
148,NCT04038619,5,"Patients with a history of immunosuppressant (infliximab, vedolizumab etc) use before FMT can be allowed if last dose was administered >= 3 months prior to FMT treatment when used for the treatment of conditions other than for ICI- induced GI toxicities (e.g., infliximab is used in the treatment of Crohn’s disease, rheumatoid arthritis, plaque psoriasis, and vedolizumab is used in treating ulcerative colitis)",0.9675002098083496,true
251,NCT04434040,23,Women of childbearing potential (pre-menopausal) must have a negative serum or urine pregnancy test within 7 days prior to start of therapy. A woman is defined as pre-menopausal if she is less than 12 months from last menstrual period with no identified cause other than menopause (medication induced amenorrhea is not acceptable). Pregnancy test is not required in women who are surgically sterile via bilateral salpingo-oophorectomy or hysterectomy,0.9674186706542969,true
40,NCT03277638,15,The treating physician expects that the patient will not require more than physiologic replacement dose of steroids defined as4 mg of dexamethasone per day or its equivalent.,0.9670819640159607,true
30,NCT03180268,5,"GTR must be confirmed on post-operative imaging following the most recent surgery. For protocol enrollment, the assessment of GTR will be made at each site. However, submission of both pre-operative and post-operative MRIs is required for patients. If a second surgery is performed, submission of post-operative MRI is required and pre-operative MRI is required only if obtained. All sequences obtained in the pre- and post-operative MR imaging are to be submitted to National Radiology Group (NRG) Oncology for study registration. The post-operative MRI must be completed within sufficient time to permit step 1 registration within 180 days of the initial resection. These same conditions apply in the setting of a second surgical procedure, although if a second surgery is completed, step 1 registration must still occur with 180 days of initial surgery. Computed tomography (CT) imaging is not required, but may be obtained if desired clinically, for instance to assess calcifications or hyperostosis",0.9669994711875916,true
197,NCT04305834,10,May have had chemotherapy in any line,0.96693354845047,true
204,NCT04332367,14,"International normalized ratio (INR) =< 1.5, and a partial thromboplastin time (PTT) =< 5 seconds above the ULN (unless receiving anticoagulation therapy). Patients receiving warfarin must be switched to low molecular weight heparin or edoxaban or show stability on another Food and Drug Administration (FDA) approved oral anticoagulant with stable coagulation profile prior to first dose of protocol therapy. There may be no active bleeding (that is, no bleeding within 14 days prior to first dose of protocol therapy) or pathological condition present that carries a high risk of bleeding (for example, tumor involving major vessels or known varices)",0.9669109582901001,true
493,NCT04974671,14,"Serum creatinine =< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance (glomerular filtration rate [GFR] can also be used in place of creatinine or creatinine clearance [CrCl]) >= 30 mL/min for subject with creatinine levels > 1.5 X institutional ULN (should be performed within 28 days of protocol treatment)
* Creatinine clearance should be calculated per institutional standard
* IF SBRT will be delivered to a lesion in or abutting the kidney",0.9667971730232239,true
352,NCT04671667,13,"Patient must not expect to conceive or father children by using by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse while on study treatment, and continue for 120 days after the last dose of study treatment",0.9666824340820312,true
99,NCT03618550,16,Hemoglobin-adjusted diffusing capacity for carbon monoxide >= 50%. (If unadjusted carbon monoxide diffusing capability test [DLCO] is >= 50% then there is no need to calculate adjusted.),0.9665558934211731,true
194,NCT04305834,6,"Histologically or cytologically confirmed diagnosis of:
* Estrogen-receptor positive and/or progesterone receptor positive breast cancer determined by immunohistochemistry (IHC) methods according to the local institution standard protocol
* HER2-negative breast cancer defined as negative if the IHC status is 0 or 1+, or if IHC is 2+ and in situ hybridization assay is negative per American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines",0.9664298295974731,true
183,NCT04189757,17,"Women of childbearing potential (WOBP) must have a negative serum or urine pregnancy test. WOBP and males must be willing to use highly effective methods of birth control prior to starting therapy. Woman of childbearing potential (WOCBP) who are sexually active must use highly effective methods of contraception during treatment and for one week after the last dose of acalabrutinib. For male subjects with a pregnant or non-pregnant WOCBP partner, should use barrier contraception even if they have had a successful vasectomy",0.966392993927002,true
206,NCT04332367,17,"If sexually active, must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods)",0.9659310579299927,true
127,NCT03761108,3,"Phase 1, Part 1 (Dose Escalation): Patients with MM who have exhausted all therapeutic options that are expected to provide meaningful clinical benefit, either through disease relapse, treatment refractory disease or intolerance of the therapy and including either: a. Progression on or after at least 3 lines of therapy, or intolerance of therapy, including a proteasome inhibitor, an Immunomodulatory agent (IMiD), and an anti-CD38 antibody, OR b. Progression on or after an anti-CD38 antibody and have disease that is ""double refractory"" to a proteasome inhibitor and an IMiD, or intolerance of therapy. The anti-CD38 antibody may have been administered alone or in combination with another agent such as a proteasome inhibitor (PI). Refractory disease is defined as lack of response or relapse within 60 days of last treatment.",0.9658657908439636,true
433,NCT04858334,22,Patients must not expect to conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse for the duration of their participation in the study and for 6 months after the last dose of protocol treatment for female patients and for 3 months after the last dose of protocol treatment for male patients. Patients must also not donate sperm while on protocol treatment and for 3 months after the last dose of protocol treatment. Patients must also not breast-feed while on protocol treatment and for 1 month after the last dose of protocol treatment,0.9657641649246216,true
378,NCT04691817,47,"Agreement to follow appropriate contraception guidelines: Requirements for contraception and pregnancy testing for a clinical trial should encompass all investigational medicinal products (IMPs) as well as protocol-mandated non-investigational medicinal products (NIMPs) such as background therapy, and the measures to be followed should be based on the medicinal product with the highest risk. Contraception requirements for marketed IMPs or NIMPs should be based on recommendations in the Summary of Product Characteristics (SmPC) or, if there is no SmPC, national prescribing information. Length of time required for abstinence or use of contraceptives should take into account the reproductive toxicity profile, including genotoxicity and teratogenicity, the size of the molecule, and the number of doses. In the absence of specific delayed-toxicity concerns or safety hypotheses, the following guidelines should be used:
* Single dose studies: 
** Small molecules: 5 elimination half-lives or 14 days after the last dose, whichever is longer
** Large molecules: 2 elimination half-lives or 28 days after the last dose, whichever is longer
* Multiple dose studies:
** Small molecules: 5 elimination half-lives or 28 days after the last dose, whichever is longer
** Large molecules: 2 elimination half-lives or 28 days after the last dose, whichever is longer",0.9655405879020691,true
52,NCT03488693,2,"Patients must have been treated by breast conserving surgery (BCS) or mastectomy
Patients must have been treated by breast conserving surgery (BCS) or mastectomy with clear margins of excision
* Patients treated by BCS with focally positive margins for invasive breast cancer or ductal carcinoma in situ (DCIS) (involving < 3 high power fields) are eligible if additional surgery is not possible, e.g. posterior margin positive and deep resection margin abuts the chest wall or anterior margin positive and superficial resection margin abuts the skin; boost radiotherapy must be administered for positive margins as described above",0.965087354183197,true
191,NCT04270175,3,Prior pomalidomide exposure allowed if ≥ PR achieved and no disease progression occurred within 60 days of last dose received,0.9650396108627319,true
424,NCT04858009,8,"Distant metastatic disease of peritoneum may be visualized on imaging:
* Positive peritoneal cytology
* Limited carcinomatosis on diagnostic laparoscopy or laparotomy
* KRASD assay positive peritoneal washings/cytology",0.9649671316146851,true
205,NCT04332367,15,"Serum creatinine =< 1.5 times the ULN; or if serum creatinine is > 1.5 times the ULN, creatinine clearance (measured via 24-hour urine collection) must be >= 40 mL/minute",0.9646086096763611,true
391,NCT04742634,6,"Willing to comply with the treatment assignment:
* Intent to proceed with DEC-C therapy if one or more variants detected prior to transplant persists at Day 30 post-transplant with a variant allele frequency of >= 0.5%.
* Intent to proceed with standard of care as determined by the treating physician on the observation arm (no DEC-C intervention) if no variants detected prior to transplant persist at Day 30 post-transplant with a variant allele frequency of >= 0.5%.",0.9639802575111389,true
254,NCT04484012,5,"Documented CD19+ mantle cell lymphoma (MCL) by flow cytometry or immunohistochemistry (IHC) (from biopsy) if prior CD19 directed therapy was previously used
* BM is optional at enrollment IF patient already has biopsy proven disease",0.9639264941215515,true
33,NCT03186898,2,"Appropriate stage for study entry based on the following diagnostic workup:
* All patients must have computed tomography (CT) scan chest/abdomen/pelvis with multiphasic liver CT scan prior to registration; if CT contrast is contraindicated, CT chest without contrast and magnetic resonance imaging (MRI) of abdomen is permitted
* Participants must have measurable disease at study entry, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 2 cm with conventional techniques or as > 1 cm with spiral CT scan
* Patient must have 3 or fewer single or multinodular tumors; for patients with a single lesion, lesion must be 15 cm or less in greatest dimension; for patients with two lesions, no lesion may be greater than 10 cm in greatest dimension; for patients with three lesions, no lesion may be greater than 6 cm in greatest dimension; portal vein involvement or thrombosis combined with a single lesion that is >= 1 cm and =< 15 cm in greatest dimension is allowed",0.963879406452179,true
499,NCT05002816,8,Total bilirubin =< 1.5 X upper limit of normal (ULN) (isolated bilirubin >= 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin < 35%),0.96355140209198,true
0,NCT02452008,1,"Have metastatic castration-resistant prostate cancer, are chemo-naïve for mCRPC (however, six cycles of docetaxel are allowed in hormone-sensitive disease), and have progressed on abiraterone treatment (patients may have had prior therapy including sipuleucel-T, radium-223, abiraterone, ketoconazole, and/or Tak-700); progression on abiraterone is defined as
* Radiologic progression by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 and Prostate Cancer Working Group (PCWG)2 criteria, or 
* PSA progression on abiraterone:
** For responders to abiraterone: 25% or greater increase and an absolute increase of 2 ng/mL or more from the nadir, confirmed by a second value obtained 2 or more weeks later
** For non-responders to abiraterone: 25% increase above baseline with an increase in absolute value of 2 ng/mL or more after 12 weeks of treatment",0.9633359313011169,true
420,NCT04852887,12,"Patients may be premenopausal or postmenopausal at the time of pre-entry/Step 1. For study purposes, postmenopausal is defined as:
* Age 56 or older with no spontaneous menses for at least 12 months prior to pre-entry/Step 1; or a documented hysterectomy; or
* Age 55 or younger with no spontaneous menses for at least 12 months prior to pre-entry/Step 1 (e.g., spontaneous or secondary to hysterectomy) and with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standard; or
* Documented bilateral oophorectomy",0.9632340669631958,true
158,NCT04134260,9,Patients who have already started on post-prostatectomy GnRH agonist/antagonist for =< 180 days prior to registration are eligible (Note: patients who started on an oral antiandrogen are eligible if started =< 180 days and stopped prior to registration),0.9628704190254211,true
192,NCT04270175,8,Total bilirubin ≤ 1.5 × the upper limit of the normal range (ULN) (Total bilirubin ≥ 1.5 x ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%),0.9628634452819824,true
23,NCT03161431,14,"Screening laboratory values must meet the following criteria and should be obtained within 14 days prior to first dose: WBC > 3000/µL Neutrophils > 1500/ µL Platelets > 100,000/µL Hemoglobin > 9.0 g/dL (may have been transfused) Creatinine < 1.5 mg/dL AST/ALT < 2.5 X ULN for subject with no liver metastases < 5 X ULN for subjects with liver metastases Bilirubin < 1.5 mg/dL (unless diagnosed with Gilbert's syndrome, who can have total bilirubin < 3.0 mg/dL) INR or PT < 1.5 X ULN unless the subject is receiving anticoagulant therapy aPTT or PTT < 1.5 X ULN unless the subject is receiving anticoagulant therapy",0.9607252478599548,true
10,NCT02734537,16,"Women must not be pregnant or breast-feeding due to exposure to cisplatin chemo-and/or radiotherapy; females of childbearing potential must have a blood or urine study within 2 weeks prior to randomization to rule out pregnancy; a female of childbearing potential is any woman, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)",0.9598290920257568,true
364,NCT04691817,7,"No greater than CTCAE v5 grade 3 toxicity on prior immune checkpoint inhibitor therapy that was at least possibly attributable to prior immune checkpoint therapy, in the investigator’s opinion",0.9597678184509277,true
296,NCT04548752,34,"Patients must not have active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment",0.9592284560203552,true
119,NCT03728335,19,"Seronegative for human immunodeficiency virus (HIV) antigen/antibody (Ag/Ab) combo, hepatitis C virus (HCV), active hepatitis B virus (HBV) (surface antigen negative), and syphilis (rapid plasma reagin [RPR])
* If positive, hepatitis C ribonucleic acid (RNA) quantitation must be performed",0.9589211940765381,true
403,NCT04768426,9,Has completed adjuvant radiation if planned. Patients who received low dose capecitabine concurrent with radiation as a radiosensitizer are eligible,0.9584062695503235,true
409,NCT04768426,20,Patients must enroll within 8 weeks of completion of definitive surgery or adjuvant radiotherapy if indicated,0.9573695659637451,true
432,NCT04858334,21,"Patient must not be pregnant or breast-feeding due the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to Step 1 randomization to rule out pregnancy. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)",0.9551517963409424,true
285,NCT04548752,15,Patients must not have had prior therapy with PARP inhibitors,0.9528285264968872,true
286,NCT04548752,16,Patients must not have had a prior diagnosis of immunodeficiency or receiving systemic steroid therapy (defined as >= 10 mg prednisone or equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment,0.9523568749427795,true
181,NCT04189757,15,Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) < 2.5 x upper limit of normal or < 5 x upper limit of normal if hepatic metastases are present. Gilbert’s disease is allowed,0.9522714614868164,true
359,NCT04671667,26,"Patient must not have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed",0.9514946341514587,true
284,NCT04548752,14,"Patients must not have had prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or any other immune checkpoint inhibitors",0.9508275985717773,true
242,NCT04423211,24,"Patient must not have completed a course of prior pelvic external beam radiation therapy that would overlap with SOC RT fields used in this protocol, such that normal tissue constraints cannot be met",0.9503499865531921,true
301,NCT04579224,3,Participant must have had progression of disease following prior therapy at the discretion of the treating investigator,0.9491108655929565,true
323,NCT04585958,25,"For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated",0.9478899240493774,true
404,NCT04768426,12,Bilirubin =< 1.5 times the specific institutional upper limit of normal (ULN). Exception: If Gilbert’s syndrome; then =< 5 times ULN,0.9460951089859009,true
382,NCT04713046,5,PATIENT: Patients with a Food and Drug Administration (FDA)-approved indication to receive an anti-programmed cell death protein-1 (PD-1) or anti-programmed death-ligand 1 (PD-L1) monoclonal antibody must have received at least one cycle of this therapy prior to receiving treatment on this trial,0.9457860589027405,true
471,NCT04963153,5,"Patients must have measurable disease, as defined by Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Previously irradiated lesions cannot be counted as target lesions unless there has been demonstrated progression in the lesion since radiotherapy and no other lesions are available for selection as target lesions",0.945742666721344,true
494,NCT04974671,20,"Female subjects of childbearing must use an effective form of birth control during this study. Acceptable and highly effective birth control methods include intra-uterine hormone releasing system as well as other methods of birth control including consistent use of an approved oral contraceptive (birth control pill), an implantable contraceptive, an injectable contraceptive, a double-barrier method, or true abstinence. Oral, implantable, or injectable contraceptives are only considered effective if used properly and started at least 30 days prior to the screening visit and continue for 120 days after last dose of study drug. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 6 months after the last dose of study therapy.",0.9456892609596252,true
237,NCT04423211,3,Patient must have had a radical prostatectomy (RP) as definitive therapy for histopathologically-proven prostatic adenocarcinoma,0.9428002834320068,true
223,NCT04375384,3,Patients must have received previous treatment with immunotherapy with PD-1 inhibitor alone or in combination with chemotherapy,0.9417949318885803,true
486,NCT04971499,6,Participants must have received an anti-PD-1/PD-L1 monoclonal antibody (mAb) as part of their most recent line of therapy prior to enrollment in the study.,0.941788911819458,true
276,NCT04548752,4,Patients must have had a CT or MRI showing stable or responding disease on first line platinum-based chemotherapy within 30 days prior to registration,0.9411937594413757,true
488,NCT04971499,10,"Have available archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion. Formalin-fixed, paraffin embedded (FFPE) tissue blocks are preferred to slides.
* Newly obtained biopsies are preferred to archived tissue, but archived sample can be used at baseline provided that the patient has only had anti-PD-1/L1 based regimen since obtaining the sample.
* Biopsies may be taken from any amenable lesion, but it is preferable to use the same lesion throughout. 
* Biopsy may be taken from previously irradiated lesions only if they have progressed since radiation therapy.
* Patient may still be eligible for study if tumor is not amenable to safe biopsy or biopsy is judged by patient or treating physician to not be in their best interest.",0.9409428238868713,true
8,NCT02734537,8,Patients with a history of a curatively treated malignancy must be disease-free for at least two years except for carcinoma in situ of cervix and/or non-melanomatous skin cancer; patients must not have received chemotherapy or investigational therapy within two years of surgical resection of the primary tumor,0.9404645562171936,true
346,NCT04671667,6,Patient must have had prior radiation to the area of recurrent or second primary tumor. This is defined as > 50% of the presurgical tumor volume having previously received a dose of > 45 Gy as determined by the treating radiation oncologist,0.9395918846130371,true
350,NCT04671667,11,Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible,0.9362782835960388,true
122,NCT03734692,4,"Patients must be platinum-sensitive, defined as having a progression free interval (PFI) of more than 6 months (180 days) from any platinum therapy. Patients are allowed to have had other lines of therapy since last platinum if PFI after platinum therapy meets platinum sensitive criteria.",0.935590386390686,true
229,NCT04415944,14,Adequate contraception and negative pregnancy test if pregnancy possible,0.9354543089866638,true
199,NCT04305834,12,Patients who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and registration,0.9350607991218567,true
246,NCT04434040,6,"Evidence of ctDNA in blood sample collected after completion of all local and systemic neoadjuvant therapy (preoperative chemotherapy) surgery and radiation, confirmed by central testing. Detection of any tumor specific mutations (TSMs) within the sample will be considered positive for purposes of study eligibility",0.934584379196167,true
445,NCT04876456,5,"Must have progressed after first-line cisplatin based combination chemotherapy AND demonstrated progression following at least one salvage regimen for advanced germ cell neoplasm and now considered incurable with standard therapies, including further chemotherapy or surgery
* “Failure” of prior therapy is defined as:
** A > 25% increase in the products of the perpendicular diameters of measurable tumor masses during prior therapy which are not amenable to surgical resection
** The presence of new tumors that are not amenable to surgical resection
** An increase in alpha-fetoprotein (AFP) or beta-human chorionic gonadotropin (beta-HCG) (two separate determinations at least one week apart are required if rising tumor markers are the only evidence of failure)
* NOTE: Subjects with clinically growing teratoma (normal declining tumor markers and radiographic or clinical progression) should be considered for surgery",0.9343376755714417,true
357,NCT04671667,24,"Patient must not have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist [registered trademark]) are live attenuated vaccines and are not allowed",0.9322863221168518,true
22,NCT03161431,10,"Prior disease progression on anti-PD1 therapy (i.e., anti-PD1 or anti-PD-L1, including prior adjuvant). Prior anti-PD1 therapy must have been completed prior to first dose of SX-682, and all adverse events related to prior therapy have either returned to baseline or stabilized (other than endocrine toxicity for which medical replacement therapy is in place).",0.9319822192192078,true
244,NCT04434040,4,Patients must have received neoadjuvant chemotherapy prior to breast surgery,0.931766152381897,true
314,NCT04585958,10,Patients must have had at least one prior line of cytotoxic chemotherapy,0.9280571341514587,true
299,NCT04567771,2,"Must have undergone an open or robotic hysterectomy (total abdominal, vaginal, radical, or total laparoscopic) for carcinoma of the cervix or endometrium",0.9260944724082947,true
438,NCT04858334,37,"Patient must not be considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled ventricular arrhythmia, recent (within 3 months) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high resolution computed tomography (HRCT) scan or any psychiatric disorder that prohibits obtaining informed consent",0.9251866340637207,true
290,NCT04548752,27,Participants must have a serum creatinine =< the institutional (I)ULN OR measured OR calculated creatinine clearance >= 50 mL/min using the following Cockcroft-Gault Formula. This specimen must have been drawn and processed within 14 days prior to registration,0.9244771003723145,true
398,NCT04742634,18,"Decitabine has been shown to be teratogenic in animal studies and the use of intravenous (IV) decitabine in the first trimester of pregnancy has been associated with major birth defects. Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men and women treated or enrolled in this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 6 months after completion of the study.",0.9237977266311646,true
411,NCT04781192,6,Measurable disease with at least 1 lesion that qualifies as a Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 target lesion (TL) at baseline. Previously irradiated lesion cannot be considered as target lesion (TL) except in cases of documented progression of the lesion since the completion of radiation therapy,0.9233863949775696,true
292,NCT04548752,30,Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial provided it does not require concurrent therapy,0.9227921366691589,true
482,NCT04966481,14,"The effects of palbociclib and cetuximab on the developing human fetus are unknown. For this reason and because CDK 4/6 inhibitors are known to be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she must inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of the study, and 3 months after completion of the study.",0.9181566834449768,true
3,NCT02452008,5,Must have had prior abiraterone treatment,0.9178319573402405,true
39,NCT03277638,14,The patient must have completed chemoradiation with radiation therapy and temozolomide of the primary tumor according to standards of care,0.9088516235351562,true
198,NCT04305834,11,Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] grade =< 1) from the acute side effects of chemotherapy (except for residual alopecia or residual grade 2 peripheral neuropathy). A washout period of at least 21 days is required between last chemotherapy dose and registration (provided the patient did not receive radiotherapy),0.906958818435669,true
361,NCT04671667,29,"Patient must not have a known history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or known active hepatitis C virus (defined as HCV ribonucleic acid [RNA] [qualitative] is detected) infection
* NOTE: No testing for hepatitis B and hepatitis C is required unless mandated by a local health authority",0.90574049949646,true
474,NCT04963153,19,"Patients with a history of prostate cancer (T2NXMX or lower with Gleason score =< 7) treated with definitive intent (surgically or with radiation therapy) at least 1 year prior to study entry are eligible, provided that the subject is considered prostate cancer-free and the following criteria are met: 
* Patients who have undergone radical prostatectomy must have undetectable prostate specific antigen (PSA) for > 1 year and at screening
* Patients who have had radiation must have a PSA doubling time > 1 year (based on at least 3 values determined >1 month apart) and a total PSA value that does not meet Phoenix criteria for biochemical recurrence (i.e., < 2.0 ng/mL above nadir)
* Patients with untreated low-risk prostate cancer (Gleason score =< 6) on active surveillance with PSA doubling time >1 year (based on at least 3 values determined > 1 month apart) are also eligible",0.9044556021690369,true
155,NCT04134260,4,"Pathologically node positive disease with nodal involvement only in the pelvis in the prostatectomy specimen or nodal disease on imaging at time of recurrence (including external iliacs, internal iliacs, and/or obturator nodes); peri-prostatic and peri-rectal nodes can also be considered regional lymphadenopathy and are allowed",0.9029739499092102,true
200,NCT04305834,13,"Absence of central nervous system (CNS) involvement unless they meet ONE of the following criteria:
* Untreated brain metastases (e.g., lesions < 1 cm) not needing immediate local therapy
* Previously treated brain metastases not needing immediate local therapy
** At least 6 days from the last date of prior therapy completion (including radiation and/or surgery) to starting the study treatment
** Clinically stable CNS tumor at the time of screening and not receiving steroids and/or enzyme-inducing anti-epileptic medications for brain metastases",0.9002295136451721,true
index,nct_id,display_order,candidate_criteria_text,score,hedging
173,NCT04189757,4,Patients who were on ibrutinib-rituximab maintenance and who develop ibrutinib associated toxicities/ibrutinib associated reasons for discontinuation (other than disease progression) are allowed to continue rituximab and SWITCH to acalabrutinib,0.9989938139915466,false
452,NCT04883242,8,Prior autologous stem cell transplant is allowed; patients must be >= 6 months post- autologous stem cell transplantation to enroll,0.9988667964935303,false
317,NCT04585958,16,"Absolute neutrophil count >= 1,000/mcL (within 14 days of randomization/enrollment)
* No administration of granulocyte colony-stimulating factor (G-CSF) is allowed within 1 week prior to screening assessment",0.9987267851829529,false
247,NCT04434040,7,Concurrent receipt of bone modifying agents (bisphosphonates or rank-ligand inhibitors) is allowed,0.9987115859985352,false
415,NCT04781192,17,"Total bilirubin =< 1.5 x institutional upper limit of normal, (biliary stenting or percutaneous biliary drainage are allowed for cancer related biliary obstruction)
* Exception: Patients with confirmed Gilbert’s syndrome (persistent or recurrent hyperbilirubinemia that is predominantly unconjugated in the absence of hemolysis or hepatic pathology), who will be allowed only in consultation with their physician",0.9986146688461304,false
498,NCT05002816,4,"Prior line of therapy must include immunomodulatory imide drug (iMID), proteasome inhibitor, and anti-CD38 monoclonal antibody. Prior elotuzumab is allowed",0.9984481334686279,false
53,NCT03488693,3,Post-mastectomy positive margins for invasive breast cancer and/or DCIS is not allowed,0.9965627789497375,false
145,NCT03900793,25,Patients with >= trace protein on urinalysis at screening will be allowed to enroll in the study at investigator discretion. A baseline urine protein creatinine ratio (UPC) should be obtained for patients with >= trace protein on urinalysis for consideration regarding dose modification requirements,0.9950730204582214,false
